Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHNFXR)

Drug Name
Chimeric Antigen Receptor Modified T cells Targeting CD19 Drug Info
Indication
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Phase 1/2 [1]
Lymphoma 2A80-2A86 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMHNFXR

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
B-lymphocyte surface antigen B4 (CD19) DTT CD19 5.758 6.211 6.083 5.396
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease leukaemia
ICD Disease Classification 2A60-2B33
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma